Table of Contents
SRX Medicine
Volume 2010 (2010), Article ID 326840, 5 pages
Clinical Study

The Effect of Amlodipine on Oxidative Stress in Patients with Type 2 Diabetes

Department of Internal Medicine, Dokkyo Medical University, Koshigaya Hospital, Koshigaya 343-8555, Japan

Received 2 September 2009; Revised 7 October 2009; Accepted 13 October 2009

Copyright © 2010 Kohzo Takebayashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Libby, “Current concepts of the pathogenesis of the acute coronary syndromes,” Circulation, vol. 104, no. 3, pp. 365–372, 2001. View at Google Scholar
  2. A. Warnholtz, G. Nickenig, E. Schulz et al., “Increased NADH-oxidase-mediated superoxide production. In the early stages of atherosclerosis evidence for involvement of the renin-angiotensin system,” Circulation, vol. 99, no. 15, pp. 2027–2033, 1999. View at Google Scholar
  3. R. P. Mason, M. F. Walter, M. W. Trumbore, E. G. Olmstead Jr., and P. E. Mason, “Membrane antioxidant effects of the charged dihydropyridine calcium agonist amlodipine,” Journal of Molecular Cellular Cardiology, vol. 31, no. 11, pp. 275–281, 1999. View at Google Scholar
  4. T. Yu, I. Morita, K. Shimokado, T. Iwai, and M. Yoshida, “Amlodipine modulates THP-1 cell adhesion to vascular endothelium via inhibition of protein kinase C signal transduction,” Hypertension, vol. 42, no. 3, pp. 329–334, 2003. View at Publisher · View at Google Scholar · View at PubMed
  5. C. Patrono and G. A. FitzGerald, “Isoprostanes: potential markers of oxidant stress in atherothrombotic disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 11, pp. 2309–2315, 1997. View at Google Scholar
  6. M. P. Reilly, D. Praticó, N. Delanty et al., “Increased formation of distinct F2 isoprostanes in hypercholesterolemia,” Circulation, vol. 98, no. 25, pp. 2822–2828, 1998. View at Google Scholar
  7. K. Takebayashi, S. Matsumoto, Y. Aso, and T. Inukai, “Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2214–2217, 2006. View at Publisher · View at Google Scholar · View at PubMed
  8. H. Helmersson and S. Basu, “F2-isoprostane excretion rate and diurnal variation in human urine,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 61, no. 3, pp. 203–205, 1999. View at Publisher · View at Google Scholar
  9. K. Takebayashi, Y. Aso, and T. Inukai, “Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes,” Metabolism, vol. 53, no. 6, pp. 693–699, 2004. View at Publisher · View at Google Scholar
  10. G. Davì, G. Ciabattoni, A. Consoli et al., “In vivo formation of 8-iso-prostaglandin and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation,” Circulation, vol. 99, no. 2, pp. 224–229, 1999. View at Google Scholar
  11. J. Nourooz-Zadeh, J. Tajaddini-Sarmadi, S. McCarthy, D. J. Betteridge, and S. P. Wolff, “Elevated levels of authentic plasma hydroperoxides in NIDDM,” Diabetes, vol. 44, no. 9, pp. 1054–1058, 1995. View at Google Scholar
  12. T. F. Luscher, R. R. Wenzel, P. Moreau, and H. Takese, “Vascular protective effects of ACE inhibitors ans calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular disease,” Cardiovascular Drugs and Therapy, vol. 9, no. 8, supplement 3, pp. 509–523, 1995. View at Google Scholar
  13. X. Zhang and T. H. Hintze, “Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent,” Circulation, vol. 97, no. 6, pp. 576–580, 1998. View at Google Scholar
  14. K. Jamerson, M. A. Weber, G. L. Bakris et al., “Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients,” The New England Journal of Medicine, vol. 359, no. 23, pp. 2417–2428, 2008. View at Publisher · View at Google Scholar · View at PubMed